Pharmacological postconditioning against myocardial infarction with a slow-releasing hydrogen sulfide donor, GYY4137 by Karwi, Qutuba G. et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/93888/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Karwi, Qutuba, Whiteman, Matthew, Wood, Mark E., Torregrossa, Roberta and Baxter, Gary 2016.
Pharmacological postconditioning against myocardial infarction with a slow-releasing hydrogen
sulfide donor, GYY4137. Pharmacological Research 111 , pp. 442-451. 10.1016/j.phrs.2016.06.028
file 
Publishers page: http://dx.doi.org/10.1016/j.phrs.2016.06.028
<http://dx.doi.org/10.1016/j.phrs.2016.06.028>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
11
PHARMACOLOGICAL POSTCONDITIONING AGAINST2
MYOCARDIAL INFARCTION WITH A SLOW-RELEASING 3
HYDROGEN SULFIDE DONOR, GYY41374
5
Qutuba G Karwia, Matthew Whitemanb, Mark E. Woodc,6
Roberta Torregrossab, Gary F Baxtera7
8
9
a School of Pharmacy and Pharmaceutical Sciences, Cardiff University, UK; 10
b Medical School, University of Exeter, UK; 11
c School of Biosciences, University of Exeter, UK12
13
14
Abbreviated running head: Postconditioning with GYY413715
16
Keywords: postconditioning, hydrogen sulfide, ischemia-reperfusion, myocardial 17
infarction, reperfusion18
19
Chemical compounds studied in this article20
GYY4137-morphilino salt (PubChem CID: 469337261), LY294002 (PubChem CID: 21
3973), N-Nitro-L-arginine methyl ester hydrochloride (PubChem: 39836)22
23
24
Address for correspondence:25
Professor G F Baxter26
School of Pharmacy and Pharmaceutical Sciences27
Redwood Building28
King Edward VII Avenue29
Cardiff CF10 3NB30
United Kingdom31
32
Telephone: +44 (0)29 2087 630933
Facsimile: +44 (0)2934
Email: baxtergf@cardiff.ac.uk35
2ABSTRACT36
Exogenous hydrogen sulfide (H2S) protects against myocardial ischemia/reperfusion 37
injury but the mechanism of action is unclear. The present study investigated the 38
effect of GYY4137, a slow-releasing H2S donor, on myocardial infarction given 39
specifically at reperfusion and the signalling pathway involved. Thiobutabarbital-40
anesthetised rats were subjected to 30 minutes of left coronary artery occlusion and 41
2 hours reperfusion. Infarct size was assessed by tetrazolium staining. In the first 42
study, animals randomly received either no treatment or GYY4137 (26.6, 133 or 266 43
µmol kg-1) by intravenous injection 10 minutes before reperfusion. In a second 44
series, involvement of PI3K and NO signalling were interrogated by concomitant 45
administration of LY294002 or L-NAME respectively and the effects on the 46
phosphorylation of Akt, eNOS, GSK-3β and ERK1/2 during early reperfusion were 47
assessed by immunoblotting. GYY4137 266 µmol kg-1 significantly limited infarct size 48
by 47% compared to control hearts (P<0.01). In GYY4137-treated hearts,49
phosphorylation of Akt, eNOS and GSK-3β was increased 2.8, 2.2 and 2.2 fold50
respectively at early reperfusion. Co-administration of L-NAME and GYY4137 51
attenuated the cardioprotection afforded by GYY4137, associated with attenuated 52
phosphorylation of eNOS. LY294002 totally abrogated the infarct-limiting effect of 53
GYY4137 and inhibited Akt, eNOS and GSK-3β phosphorylation. These data are the 54
first to demonstrate that GYY4137 protects the heart against lethal reperfusion injury 55
through activation of PI3K/Akt signalling, with partial dependency on NO signalling 56
and inhibition of GSK-3β during early reperfusion. H2S-based therapeutic 57
approaches may have value as adjuncts to reperfusion in the treatment of acute 58
myocardial infarction.59
60
3List of abbreviations61
AAR = area at risk62
Akt = protein kinase B63
DATS = diallyltrisulfide64
eNOS = endothelial nitric oxide synthase65
ERK1/2 = Extracellular signal-regulated kinases 1/2 (p42/p44 mitogen activated66
protein kinase)67
GSK-3β = glycogen synthase kinase-3 Beta68
GYY4137 = morpholin-4-ium 4-methoxyphenyl-morpholino-phosphinodithioate69
H2S = hydrogen sulfide70
IPost-C = ischemic postconditioning71
mPTP = mitochondrial permeability transition pore72
NO = nitric oxide73
PBS = phosphate buffered saline74
PI3K = Phosphatidylinositol-3-kinase75
RISK = reperfusion injury salvage kinase (signalling pathway)76
77
41. INTRODUCTION78
In acute myocardial infarction, prompt restoration of coronary blood flow with79
appropriate reperfusion interventions is essential to salvage ischemic myocardium. 80
Paradoxically, sudden reperfusion induces further irreversible cell injury and death81
beyond that caused by ischemia. Therefore, reperfusion injury contributes to overall 82
clinical outcome since ultimate infarct size will be determined by both ischemic and 83
reperfusion injuries (Ferdinandy et al., 2014). Reperfusion injury is a challenging but 84
important therapeutic target. The molecular pathology of reperfusion injury is 85
complex and is likely to involve overwhelming oxidative/nitrosative stress, sudden 86
intracellular pH normalisation and cytosolic Ca2+ oscillation, precipitating opening of 87
the mitochondrial permeability transition pore (mPTP) during the early moments of88
reperfusion which initiates necrosis (Sluijter et al., 2014, Cabrera-Fuentes et al., 89
2016).90
91
Ischemic postconditioning (IPost-C) is an experimental manoeuvre in which very 92
brief intermittent periods of ischemia are introduced immediately after reperfusion93
(Zhao et al., 2003). This intervention has been shown to limit infarct size significantly,94
most likely through the activation of survival signalling mechanisms that reduce 95
opening of the mPTP (Hausenloy and Yellon, 2007). The so-called “reperfusion 96
injury salvage kinase” (RISK) pathway includes as key components 97
phosphatidylinositol-3-kinase (PI3K)/Akt, and endothelial nitric oxide synthase 98
(eNOS). Other kinases have been described as part of the RISK pathway including 99
extracellular regulated kinase (ERK1/2; p42/p44 mitogen activated protein kinase) 100
and glycogen synthase-3 (GSK-3). Although IPost-C is of limited clinical 101
applicability, a number of pharmacological approaches that mimic IPost-C have been 102
5described, including the administration of autacoids and other mediators thought to 103
activate the kinases of the RISK cascade (Burley and Baxter, 2009).104
105
Hydrogen sulfide (H2S) has attracted considerable interest as a cardiovascular106
autacoid. Although produced endogenously within the myocardium and coronary 107
vasculature (Liu et al., 2012, Hackfort and Mishra, 2016), in coronary artery disease, 108
there may be reduced H2S production (Yong et al., 2008, Han et al., 2015, Islam et 109
al., 2015). The administration of exogenous H2S donor compounds or increasing110
endogenous production of H2S has been well documented to reduce ischemia-111
reperfusion injury in experimental models (Elrod et al., 2007, Calvert et al., 2009, 112
King et al., 2014). There is also evidence that H2S is a mediator of IPost-C (Bian et 113
al., 2006, Yong et al., 2008, Huang et al., 2012, Das et al., 2015). However, potential114
therapeutic extrapolation of this knowledge has been hindered by the limitations of 115
H2S donor compounds. Much of the experimental literature has reported studies with 116
inorganic sulfide salts (Na2S and NaSH) which are impure in commercial form and 117
unstable. Despite them being water soluble and inexpensive, a particular issue is 118
that the H2S release is largely uncontrollable as they dissociate in aqueous medium 119
instantly to generate H2S at high concentration in a short-lasting burst120
(Papapetropoulos et al., 2015). In contrast to Na2S and NaSH, GYY4137 (morpholin-121
4-ium 4-methoxyphenyl-morpholino-phosphinodithioate) is a donor compound which122
releases H2S at a slow steady rate at physiological pH and temperature (Li et al., 123
2008). Several studies have suggested that GYY4137 effectively delivers H2S in 124
various physiological systems (Li et al., 2009, Lisjak et al., 2010, Lee et al., 2011, 125
Robinson and Wray, 2012, Liu et al., 2013, Grambow et al., 2014, Meng et al., 126
2015b). Recent work by Meng et al. (2015a) showed that GYY4137 given prior to 127
6myocardial ischemia protected against injury development and improved post-128
ischemic recovery of function. However, the therapeutically relevant time window for 129
acute myocardial infarction implies administration as a postconditioning mimetic i.e. 130
immediately prior to reperfusion since this is the time at which clinical therapeutic 131
intervention can feasibly be made.132
133
The aim of the present study was to investigate for the first time the injury limiting 134
effects of GYY4137 at early reperfusion when given specifically as an adjunct to135
reperfusion in a rat model of acute myocardial infarction. We hypothesised that 136
GYY4137 was able to limit reperfusion injury when given just prior to reperfusion, 137
thereby limiting ultimate infarct size. We further hypothesised that the protective 138
action was due to H2S release and the activation of key components of the RISK 139
signalling cascade at the first minutes of reperfusion associated with 140
postconditioning, namely PI3K/Akt and eNOS.141
142
72. MATERIALS AND METHODS143
144
2.1 Animals145
Male Sprague Dawley rats, 300-350 g, were purchased from Harlan, UK. They were 146
acclimatised in the institutional animal house at constant temperature and humidity 147
on a 12 hour light/dark cycle for at least seven days prior to experimentation, with 148
free access to water and a small animal diet (Teklad global 14% protein rodent 149
maintenance diet) at all times. All handling and procedures were carried out in 150
accordance with UK Home Office Guidelines on the Animals (Scientific Procedures) 151
Act 1986, (published by the Stationery Office, London, UK). The reporting of animal 152
studies was in accordance with ARRIVE guidelines (Kilkenny et al., 2010, McGrath 153
et al., 2010).154
155
2.2 Materials156
GYY4137 was synthesised by us as previously reported (Li et al., 2008). The purity 157
of GYY4137 was determined by NMR spectroscopy (1H, 31P and 13C). It was 158
identical to a commercial sample from SigmaAldrich. The constitutive nitric oxide 159
synthase (NOS) inhibitor L-nitroarginine methyl ester (L-NAME), the 160
phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002, thiobutabarbital sodium salt 161
hydrate (Inactin® hydrate), Evans blue dye, triphenyltetrazolium chloride (TTC) and 162
dimethylsulfoxide (DMSO) were all purchased from Sigma-Aldrich, Gillingham, UK. 163
Western blotting antibodies were all sourced from Cell Signalling, UK.164
165
2.3 Acute myocardial infarction model166
Rats were anesthetised by intraperitoneal injection of thiobutabarbital sodium (200 167
mg kg-1) and maintained by intravenous supplemental dosing (75 mg kg-1) as 168
8required to maintain surgical anesthesia throughout the procedure. Body 169
temperature was maintained at 37 ± 1 °C via rectal thermometer attached to a 170
thermo-regulated blanket unit (Harvard Apparatus Ltd, Cambridge, UK). The right 171
common carotid artery was cannulated and connected to a pressure transducer to 172
measure heart rate and blood pressure throughout the procedure (Powerlab data 173
acquisition system, AD instruments, Abingdon, UK). The left jugular vein was 174
cannulated for drug administration. The trachea was cannulated via tracheotomy and 175
the animal ventilated with room air by a small animal volume controlled ventilator 176
(Hugo Sachs Elektronik, March, Germany) at a rate of 75 strokes min-1 and tidal 177
volume of 1.0 to 1.25 mL 100 g-1. The electrocardiogram was recorded using 178
standard lead lI electrodes inserted subcutaneously into the limbs and connected to 179
a Powerlab data acquisition system. A midline sternotomy was performed and the180
chest opened using a metal retractor to expose the heart. After pericardiotomy, a 4/0 181
braided silk suture (Mersilk, Ethicon Ltd, UK) was placed around the left main182
coronary artery close to its origin from the left border of the pulmonary conus. The 183
animal was left to stabilise for 20 minutes during which the two ends of the silk 184
ligature remained loose. For each animal to be included it had to achieve the 185
following hemodynamic parameters during the stabilisation period: heart rate ≥ 250 186
beats per minute, diastolic blood pressure ≥ 50 mmHg, steady sinus rhythm, no 187
signs of ischemia or arrhythmia during the stabilisation period.188
189
After stabilisation, the ligature was pulled taut through a plastic snare and fastened190
against the epicardium to induce regional ischemia for 30 minutes. Ischemia was 191
confirmed by a drop in the mean arterial pressure (MAP), a colour change of the left 192
ventricle (from red to pale), and ECG changes (ST-segment elevation). After 30 193
9minutes, the snare was released to allow reperfusion for 120 minutes. Successful 194
reperfusion was confirmed by hyperemic colour change of the ischemic tissue bed, 195
occurrence of reperfusion-induced arrhythmia during the first minute after196
reperfusion, and an increase in the MAP. 197
198
2.4 Infarct size determination199
After 120 min reperfusion, the heart was excised and perfused via the aorta with 200
saline on a modified Langendorff apparatus. After re-occluding the coronary ligature, 201
the heart was perfused with 2% Evans’ blue dye to identify the ischemic zone (area 202
at risk, AAR). The heart was then frozen at -20 ºC for 5-24 hours. The frozen heart 203
was transversely sliced at 2 mm thickness into 5-6 sections from apex to base and 204
the sections incubated with triphenyltetrazoilum chloride (TTC) 1% w/v in phosphate 205
buffered saline (PBS; pH 7.4) at 37 °C for 15 minutes. TTC is reduced to a red 206
formazan pigment in viable tissue while necrotic tissue is unstained. Stained sections 207
were fixed in 4% formalin in PBS for 24 hours before being scanned. Planimetry was208
conducted using the image analysis program Image J (version 1.47, NIH, Bethesda, 209
USA). Sections were coded so that image analysis was undertaken in a blinded210
fashion to obviate bias. Planimetric analysis determined the total ventricular area, the 211
AAR (Evans blue negative), and the infarcted area (TTC negative). These areas 212
were then converted into volumes by multiplying each total area by 2mm section 213
thickness and the infarct size was reported as a percentage of the area at risk214
volume (% I/AAR).215
216
2.5 Treatment protocols217
Treatment protocols are illustrated in Figure 1. Two separate series of experiments 218
were undertaken. The first series examined the dose-dependent effects of GYY4137 219
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on infarct size and the involvement of H2S in mediating any responses. The dose 220
range employed in these studies was derived from previous studies in the rat heart 221
ex vivo by our group (Suveren et al., 2012) and in vivo studies conducted by others 222
(Li et al., 2008, Meng et al., 2015a). Animals were randomly assigned to one of five 223
groups (Figure 1A):224
 Group 1: Control (n=9). Animals were subjected to coronary occlusion and 225
reperfusion with saline given as a slow i.v. bolus 10 minutes before 226
reperfusion.227
 Group 2-4: Each group (n=8) received GYY4137 at 26.6, 133 or 266 µmol kg-228
1, respectively) as a slow i.v. bolus (500µL min-1) 10 minutes before 229
reperfusion.230
 Group 5: Depleted GYY4137 (n=6). GYY4137 solution (100 mg mL-1) was 231
prepared in saline and left uncovered for 72 hours at room temperature to 232
dissipate all H2S, then administered at a dose of 266 µmol kg
-1 i.v. 10 minutes 233
before reperfusion.234
235
The second series of experiments explored the involvement of RISK pathway 236
components in the cardioprotective effect of GYY4137. The optimum dose of 237
GYY4137 (266 µmol kg-1) was selected from the first series and animals were 238
randomised into six treatment groups (Figure 1B).239
 Group 6: Control (n=7). Animals were subjected to coronary occlusion and 240
reperfusion with saline or DMSO 5% given as a slow i.v. bolus 15 minutes 241
before reperfusion. DMSO was used as vehicle for LY294002. Since DMSO242
exerted no effect on cardiodynamics or infarct size, saline and DMSO treated 243
animals are reported collectively.244
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 Group 7: GYY4137 (n=7). A slow bolus dose of GYY4137 (266 µmol kg-1, 500 245
µL min-1) was administered at 10 minutes before reperfusion.246
 Group 8: GYY4137 + L-NAME (n=7). An intravenous bolus dose of L-NAME 247
(20 mg kg-1) was administered 15 minutes before reperfusion followed by 248
GYY4137 (266 µmol kg-1, 500 µL min-1) 10 minutes before reperfusion.249
 Group 9: L-NAME (n=6). An intravenous bolus dose of L-NAME (20 mg kg-1) 250
was administered 15 minutes before reperfusion.251
 Group 10: GYY4137 + LY294002 (n=6). An intravenous bolus dose of 252
LY294002 (0.1 mg kg-1 in 5% DMSO) was given 15 minutes before 253
reperfusion followed by GYY4137 (266 µmol kg-1, 500 µL min-1) 10 minutes254
before reperfusion.255
 Group 11: LY294002 (n=6). A bolus dose of LY294002 (0.1 mg kg-1 in 5% 256
DMSO) was administered intravenously 15 minutes before reperfusion.257
258
In a parallel series of experiments, rats were subjected to the same interventions as 259
in groups 6 to 11 to prepare samples for biochemical analysis. After 5 minutes of 260
reperfusion, the experiment was terminated and myocardial biopsies were harvested261
from the left ventricle, rapidly frozen in liquid nitrogen then kept at −80 ºC for 262
Western blotting of Akt, eNOS, GSK-3β and ERK1/2.263
264
2.6 Western blotting analysis265
To investigate the involvement of Akt, eNOS, GSK-3β and ERK1/2, protein 266
immunoblotting was carried out to analyse protein phosphorylation at 5 minutes of 267
reperfusion. Myocardial biopsies were homogenised and lysed using a hard tissue 268
lysing kit (Stretton Scientific Ltd, Stretton, UK). Equal amounts of protein were 269
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loaded onto 10% w/v sodium dodecyl sulfate-polyacylamide gel, separated 270
electrophoretically (120 mV) and transferred onto nitrocellulose membrane 271
(Amersham, Germany). The membrane was then blocked with 5% skimmed milk for 272
2 hours and probed with the primary antibody overnight at 4 ºC. The following 273
antibodies were used: Akt (1:1000), phospho- ser473Akt (1:1000), endothelial nitric 274
oxide synthase (eNOS 1:500), phospho- ser1177eNOS (1:500), glycogen-synthase 275
kinase-3 beta (GSK-3β 1:1000), phospho- ser9GSK-3β (1:1000), extracellular signal-276
regulated kinases ERK 1/2 (1:1000), phospho- Thr202/Tyr204 ERK 1/2 (1:1000) and 277
GAPDH (1:50000). The immunoblots were probed with secondary antibody (goat278
anti-rabbit HRP, 1:15000, Cell Signalling UK) for 1 hour then probed with Super 279
Signal West Dura Extended Duration Substrate (Thermo Scientific) to visualise the 280
bands on X-ray film. The film was scanned and densitometry was conducted in a 281
blinded fashion using Image J software (1.48v, National Institutes of Health USA).282
Phosphorylated and total protein bands were normalised to corresponding GAPDH 283
bands and to baseline samples, harvested after 20 minutes of stabilisation, loaded at 284
either side of each gel.285
286
2.7 Statistical analysis287
All data are reported as arithmetic mean ± SEM. Data were analysed using 288
GraphPad Prism® software (2007, Version 5.01, USA). Cardiodynamics including 289
rate-pressure product (RPP, heart rate * systolic blood pressure) and mean arterial 290
pressure (MAP, diastolic pressure + 1/3[systolic pressure - diastolic pressure]) were291
statistically analysed using repeated measures ANOVA supported by Bonferroni’s292
post hoc test. Baseline data including body weight, RPP, and MAP passed the 293
Kolmogorov-Smirnov normality test of distribution. Infarct size data were analysed 294
13
using one way ANOVA supported by Newman-Keuls post hoc test. Differences 295
between groups were considered significant if p <0.05.296
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3. RESULTS
In series 1, 42 rats were used, of which two were excluded from final analysis, one 
due to failure of TTC staining and one rat which did not survive the ischemia-
reperfusion protocol. Thus data for 40 successfully completed experiments are 
reported. In series 2, 66 rats were employed, of which three did not complete the 
ischemia-reperfusion protocol. Thus, data from a total of 63 completed experiments
are reported in series 2: these comprised 39 completed infarct size experiments and 
24 preparations for Western blot analysis.
3.1 Hemodynamic parameters
Baseline hemodynamics for series 1 and 2 are summarised in Table 1. There was 
no significant difference in any of the parameters among the experimental groups. 
Cardiodynamics (MAP and RPP) measurements before ischemia, during ischemia 
and at the end of reperfusion are also presented in Table 1. GYY4137 had no
detectable effect on cardiodynamics during the ischemia-reperfusion protocol.
3.2 Infarct size following GYY4137 postconditioning
Series 1 examined the response to three doses of GYY4137 on infarct size (Figure 
2). AAR constituted approximately 40-60% of the total ventricular volume with no 
significant differences among the treatment groups (Figure 2A). Control infarct size 
(%I/AAR) was 52.5 ± 4.7% (Figure 2B). GYY4137 (266 µmol kg-1) produced 
significant infarct limitation when given 10 minutes before reperfusion compared to 
control hearts (27.9 ± 3.8% vs 52.5 ± 4.7%, p<0.01). This represents a 47% relative 
reduction in infarct size. In contrast, depleted-GYY4137 (produced as described in 
Alexander et al., 2015) which lacked H2S donating potential but was otherwise 
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structurally identical had no effect on infarct size at the same dose (51.9 ± 3.1%), 
confirming the dependency of GYY4137’s infarct-limiting action on H2S release.
3.3 Involvement of PI3K/Akt and eNOS in GYY4137 postconditioning
The second series of experiments was undertaken to examine components of the 
RISK signalling pathway in the protective effect of GYY4137 (Figure 3). There was 
no significant difference in the AAR among the experimental groups (Figure 3A).
GYY4137 (266 µmol kg-1) elicited a significant reduction in %I/AAR compared to
control (27.6 ± 2.0% vs 56.8 ± 3.5%, respectively, p<0.001, Figure 3B). 
Pharmacological inhibition of eNOS with L-NAME prior to GYY4137 almost halved
the cardioprotective effect of GYY4137 (41.1 ± 6.3% vs 27.6 ± 2.0%, respectively,
p<0.05), but did not abolish it (41.1 ± 6.3% vs 56.8 ± 3.5%, respectively, p<0.01, 
Figure 3B). Concomitant administration of LY294002 to inhibit PI3K activity 
completely abrogated the cardioprotective effect of GYY4137 (49.8 ± 4.2% vs 56.8 ± 
3.5%, respectively, p>0.05). Neither L-NAME nor LY294002 had any effect on 
infarct size when given alone (55.7 ±3.3% and 51.2 ± 2.7% respectively, both 
p>0.05 vs control). 
The extent of phosphorylation of Akt, eNOS, GSK-3β and ERK1/2 in early 
reperfusion was investigated with phospho-specific antibodies to determine the 
possible roles in cardioprotection by GYY4137. Immunoreactivity measurements 
were performed using myocardial tissue samples harvested from the left ventricle 5
minutes after reperfusion and are presented in Figure 4A-D. There was no 
significant difference in protein expression to GAPDH of Akt, eNOS, GSK-3β or 
ERK1/2 among any of the experimental groups. There was a significant 2.8-fold 
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increase (p<0.001 vs. control) in phospho-ser473Akt at reperfusion following 
GYY4137 treatment (Figure 4A). Prior administration of L-NAME did not limit this
increase in Akt phosphorylation. However, administration of LY294002 alone or prior 
to GYY4137 abolished Akt phosphorylation (Figure 5A). Postconditioning with 
GYY4137 also increased eNOS phosphorylation at the activating ser1177 site by 2.2-
fold in early reperfusion (p<0.01 vs. control; Figure 4B). This activation was
abrogated by prior administration of either L-NAME or LY294002. Ser9
phosphorylation of GSK-3β was also increased 2.2-fold by GYY4137 (Figure 4C). 
This phosphorylation, leading to inactivation of GSK-3β, was not affected L-NAME. 
However, pre-treatment with LY294002 prior to GYY4137 abrogated GSK-3β
phosphorylation. GYY4137 had no significant effect on the phosphorylation of 
ERK1/2 at early reperfusion (Figure 4D). 
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4. DISCUSSION
The principal observations of this study can be summarised as follows:
1. GYY4137 limited myocardial infarction in vivo when given specifically prior to
reperfusion indicating potent attenuation of lethal reperfusion injury in a 
postconditioning-like manner.
2. The infarct-limiting effect of GYY4137 at early reperfusion was mediated through 
activation of the PI3K/Akt survival cascade.
3. There was a partial dependency of GYY4137’s protective effect on increased
eNOS activation.
4. GYY4137 inhibited GSK-3β activity at early reperfusion by increasing the 
phosphorylation of its ser9 site downstream of PI3K/Akt signalling.
These findings support the hypothesis that administration of GYY4137 at reperfusion 
can protect the heart against reperfusion injury by activating the key components of 
the RISK cascade (PI3K/Akt/NO) and inhibition of GSK-3β activity.
4.1 Infarct limitation by GYY4137
The results show for the first time the effect of GYY4137, as a slow-releasing H2S 
donor, on myocardial infarction in an in vivo model. Intracellular levels of H2S are
reported to be decreased during ischaemia-reperfusion as a results of overwhelming 
ROS generation which limits H2S synthesis and increases its degradation (Vandiver 
and Snyder, 2012). GYY4137 elicited significant infarct limitation when administered 
prior to reperfusion. Depleted GYY4137 (Alexander et al., 2015) was employed as a 
control to ensure that any detectable effect was due to H2S released and not by the 
parent molecule or by-products formed from GYY4137 decomposition. Depleted
GYY4137 had no effect on infarct size and this is consistent with previous studies
18
where loss of H2S from GYY4137 was shown to be associated with loss of biological 
activity (Li et al., 2009, Whiteman et al., 2010, Fox et al., 2012, Jamroz-Wisniewska 
et al., 2014, Alexander et al., 2015).
This is the first study of pharmacological postconditioning against reperfusion injury
in vivo using GYY4137 as a stable H2S donor. Although inorganic H2S generators
(NaSH and Na2S) have been used in different experimental species, the specific 
targeting of reperfusion injury by GYY4137 in this study is novel. Several studies 
have investigated the effect of H2S against myocardial ischemia-reperfusion when 
commercially available sulfide salts were perfused or given pre-ischemia. For 
example, Johansen et al. (2006) were the first to show that NaSH limited infarct size 
in a rat isolated heart preparation, while Pan et al. (2009), Sivarajah et al. (2009), 
Zhuo et al. (2009) and Yao et al. (2012) all showed that NaSH limited infarct size in 
an in vivo rat model through diverse mechanisms. Part of this variation is arguably 
due to the unstable nature of these H2S sources, in addition to the different 
experimental conditions and end-points of interest. Using garlic derivative as an 
organic source of H2S, Zhang et al. (2001) and Chuah et al (2007) reported that
allitridum and S-allylcysteine respectively also elicited cardioprotection against 
myocardial infarction when given before ischemia. Preconditioning the heart with the 
thiol derivative S-diclofenac was also protective partially through the opening of 
mitochondrial KATP channels (Rossoni et al., 2008). Investigators also have 
examined the possibility of postconditioning the myocardium using NaSH and Na2S. 
For example, Elrod et al. (2007), Sodha et al. (2009) and Lambert et al. (2014) all
reported that Na2S protected mouse heart against myocardial infarction in vivo when 
given at reperfusion. Bibli et al. (2015) showed that a bolus dose of NaSH 10 
minutes before reperfusion then continuous infusion of NaSH till the end of 
reperfusion was required to significantly exert cardioprotection in rabbit. In 
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comparison with these results, in this study we showed that a single bolus dose of 
GYY4137 at reperfusion had a significant cardioprotective effect against myocardial 
infarction in the rat. To our knowledge, the only other long-lasting H2S donors that 
have been reported are the polysulfide diallyl trisulfide (DATS) and SG-1002, a thiol-
activated H2S donor. Despite generating 10 times less H2S than Na2S, DATS was 
shown to improve mitochondrial respiration and stimulate eNOS at reperfusion in an
in vivo mouse model of ischemia-reperfusion injury. However, DATS is a polysulfide
compound, and thus cannot be considered a pure H2S donor with the possibility of
off-target effects. Moreover, H2S release from GYY4137 is reported to last longer 
compare to DATS (Li et al., 2008, Predmore et al., 2012). In the setting of pressure-
overload-induced heart failure, SG-1002-treated hearts were protected during 
transverse aortic constriction via triggering VEGF/Akt/eNOS/NO/cGMP pathway. 
Recently, SG-1002 has successfully passed Phase I clinical study in patient with 
heart failure (ClinicalTrials.gov #NCT01989208 and #NCT02278276), by increasing 
blood H2S level and circulating NO bioavailability (Polhemus et al., 2015). However, 
none of these studies have shown that the observed effects are due to H2S release 
due to the lack of negative control (like depleted GYY4137, for example). Therefore, 
there is persuasive experimental evidence that a stable level of H2S release confers 
effective cardioprotection against ischemia-reperfusion injury. The present study 
confirms for the first time that administration of GYY4137 prior to reperfusion 
(postconditioning), rather than prior to coronary artery occlusion (preconditioning), 
exerts a marked cardioprotective effect due to H2S-releasing capacity.
4.2 GYY4137 postconditioning activates PI3K/Akt signalling
The second series of experiments aimed to explore the signalling mechanisms 
underpinning the protective effect of GYY4137. The involvement during early 
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reperfusion of specific kinase mechanisms, notably activation of PI3K/Akt and/or 
ERK1/2, activation of eNOS and inhibition of GSK-3, has attracted considerable 
attention in relation to cardiac conditioning phenomena, especially postconditioning. 
Elucidation of the RISK pathway has confirmed that it is a key modulator of 
protection against reperfusion injury in many species, although not all. Here, we 
explored the effects of pharmacological inhibition of two key components, PI3K/Akt 
and eNOS, confirmed by assessment of the phosphorylation status of these proteins. 
We found that the PI3K inhibitor LY294002 abrogated the infarct-limiting effect of 
GYY4137 which indicated the involvement of PI3K/Akt survival pathway in 
cardioprotection established by GYY4137. This was supported by the observation 
that GYY4137 increased Akt phosphorylation in left ventricular myocardium during 
early reperfusion, an effect abolished by LY294002. Li et al. (2015a) showed that 
NaSH at reperfusion limited cell death by activating PI3K/Akt pathway in aging rat 
heart and cardiomyocytes. However, Lambert et al. (2014) demonstrated that in 
diabetic rats NaSH-induced postconditioning might signal through the other arm of 
the RISK pathway, namely ERK1/2. LY294002 alone had no significant effect on 
either the infarct size or Akt phosphorylation compared to control which is consistent 
with the findings of other investigators (Wang et al., 2013, Barsukevich et al., 2015). 
This suggests that the PI3K/Akt pathway is almost inactive at basal physiological 
levels of H2S. 
We also investigated the involvement of ERK1/2 in cardioprotection established by 
GYY4137. In contrast to Akt phosphorylation, we observed no significant increase in 
ERK1/2 phosphorylation at early reperfusion following postconditioning with 
GYY4137. It has been reported by others that a bolus dose of Na2S at reperfusion 
could activate ERK1/2 and also inhibit GSK-3β (Lambert et al., 2014, Li et al., 2015b, 
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Bibli et al., 2015). However, since in our hands GSK-3β phosphorylation (leading to 
enzyme inhibition) by GYY4137 was abrogated by LY294002, this suggests it is 
downstream of PI3K/Akt, rather than ERK1/2. It again emphasises the physiological 
differences between bolus sulfide (with NaSH or Na2S) and H2S generated in a more 
physiological manner (with GYY4137).
4.3 Dependency of GYY4137-postconditioning on NO
Inhibition of NO synthesis using L-NAME had no effect on the infarct size per se
which is consistent with other investigators (Fradorf et al., 2010, Imani et al., 2011).
This observation implies that NO does not afford any cardioprotection against 
myocardial infarction at basal physiological levels. GYY4137 treatment induced an 
increase in the phosphorylation of eNOS at its activating site, ser1177 suggesting that
NO bioavailability is increased following GYY4137 treatment. L-NAME prior to
GYY4137 administration limited the phosphorylation of eNOS and partially 
attenuated infarct limitation but did not completely abolish the protective effect. 
These data suggest that enhancing NO bioavailability synergises the 
cardioprotection of GYY4137 against reperfusion injury but blocking eNOS 
phosphorylation only partially limits the cardioprotection of GYY4137, suggesting the 
involvement of parallel NO-independent pathway(s). There has been considerable 
interest in cross-regulation of NO and H2S but the nature of their interactions is 
uncertain, at least in part because of the large variation in experimental conditions.
SG-1002, H2S donor, was protective and increased NO bioavailability in an in vivo
model of heart failure (Kondo et al., 2013). An increase in NO metabolites following 
DATS treatment was also observed by Lefer and co-workers (2012) in mouse heart. 
King et al. (2014) found that H2S did not limit infarction in eNOS phospho-mutant 
22
(S1179A) or eNOS knockout mice. Considered together, these studies suggest that 
an increase in one of the gaseous mediators can eventually lead to an increase in 
the other but the picture is obscured by variations across species, pathological 
models and tissue types. The NO-dependency of H2S has recently been studied by
Bibli et al. (2015) in an in vivo model of myocardial infarction using two species, 
rabbit and mouse. Pharmacologically limiting NO availability with L-NAME did not 
limit the protection of NaSH in rabbits, while genetic mutation or pharmacological
blockade of eNOS totally abolished H2S-induced protection in mice. Dependency of 
NaSH-induced cardioprotection on NO in mice was previously reported by Sojitra et 
al. (2012). Together and in line with our data, it seems plausible that NO involvement 
in the infarct-limiting effect of H2S could be tissue and/or species-dependent. Further 
detailed work needs to be carried out for better understanding of the molecular 
pharmacology of these molecules and to enhance the clinical implementation of H2S-
delivering systems.
4.4 GYY4137 postconditioning attenuates GSK-3β phosphorylation
GSK-3β has been proposed as one of the key end effectors of some cardioprotective 
manoeuvres, particularly ischemic conditioning phenomena. It has been 
demonstrated that GSK-3β promotes the opening of mPTP during reperfusion, an 
event thought to be a major determinant of cell death (Cabrera-Fuentes et al., 2016).
In isolated cardiomyocytes, Yao et al. (2010) and Li et al. (2015b) found that NaSH
protected against hypoxia/reoxygenation induced cell death by inhibiting GSK-3β-
dependent opening of mPTP. In line with these results, the present study
demonstrated that GYY4137 increased the phosphorylation of GSK-3β at Ser9 site at 
reperfusion. This was abolished by LY294002, but not by L-NAME, suggesting that 
GYY4137 induced inhibition of GSK-3β is downstream of PI3K/Akt. There is 
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evidence that the increase in Akt phosphorylation (Hausenloy et al., 2009) and NO 
bioavailability (Burley et al., 2007) at early reperfusion may also inhibit the opening of 
mPTP. Considering these data together, it seems plausible that postconditioning with 
GYY4137 is associated with a reduced susceptibility of mPTP opening, although this 
remains to be determined by specific measurements of mPTP opening.
4.5 Study limitations
There are still questions which this study did not address and they could be 
interesting topics for further investigations. This study found that GYY4137 activates
the RISK pathway at early minutes of reperfusion to limit the infarct size where 
infarction was quantified after 2 hours of reperfusion. Nevertheless, whether 
GYY4137 could exert a comparable cardioprotection via similar or different 
mechanism(s) with longer reperfusion protocol, where there could be no-flow 
phenomena or late apoptosis, needs to be investigated. Although spent-GYY4137 
did not exert any cardioprotection, the direct effect of GYY4137 administration on the 
level of H2S in the heart and circulation needs to be measured. Similarly, measuring 
the proposed elevation in NO bioavailability as a result of activating eNOS at 
reperfusion by GYY4137 administration could also underpin the conclusion. 
4.6 Conclusion
In summary, we have demonstrated that the slow-releasing H2S donor GYY4137, 
but not its H2S-depleted control, protected the heart against lethal reperfusion injury
when administered as an adjunct treatment prior to reperfusion. This cardioprotective 
action is dependent on activation of PI3K/Akt signalling pathway at early reperfusion, 
which in turn, increases NO bioavailability by increasing eNOS phosphorylation, and 
increases the phosphorylation of GSK-3β (see Figure 5, Graphical Abstract). Thus, 
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stable slow-releasing H2S donor compounds may be promising candidates for the 
development of adjunct therapies to reperfusion for the treatment of acute 
myocardial infarction.
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FIGURE LEGENDS
Figure 1. Treatment protocols. A. Series 1 infarct studies. After surgical 
preparation, rats were stabilised for 20 minutes then subjected to 30 minutes of left 
coronary artery occlusion (CAO) followed by 120 minutes of reperfusion. Control 
rats did not receive any further intervention, while treatment groups received one of 
three GYY4137 doses or depleted GYY4137 (D-GYY4137) 10 minutes before 
reperfusion. Hearts were excised at the end of reperfusion for infarct size 
determination, n = 6-10. Arrows indicate the time of pharmacological interventions. 
B. Series 2 infarct studies. Following stabilisation, rats were subjected to 30 
minutes of left coronary artery occlusion and 120 minutes of reperfusion. Animals 
were randomised into six groups. Control heart did not receive any further 
intervention. GYY4137 was administered 10 minutes before reperfusion. LY294002
and L-NAME were administered 15 minutes before reperfusion. Hearts were excised 
at the end of reperfusion for infarct size determination, n = 6-7. Parallel groups, n=4, 
were prepared identically but hearts were excised 5 minutes after reperfusion for 
analysis by immunoblotting. Arrows indicate the time of pharmacological 
interventions.
Figure 2. Infarct size data: GYY4137 dose-response study (Series 1). Area at risk 
was determined Evans’ blue exclusion and infarction was assessed by TTC staining. 
GYY4137 was administered at 26.6, 133, or 266 µmol kg-1 10 minutes before 
reperfusion. A. area at risk as a percentage of the total ventricular volume.  B.
myocardial infarction expressed as a percentage of the area at risk. Numbers in 
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histograms indicate sample size. ** P<0.01 versus Control; † p<0.05 versus 
GYY4137 266 µmol kg-1 (one way ANOVA with Newman Keuls post hoc test). 
Figure 3. Infarct size data: GYY4137 with pharmacological inhibitors (Series 2). Area 
at risk was determined Evans’ blue exclusion and infarction was assessed by TTC 
staining. GYY4137 was administered at 266 µmol kg-1 10 minutes before 
reperfusion. LY294002 or L-NAME were given 15 minutes before reperfusion. A.
area at risk expressed as a percentage of the total ventricular volume. B. infarct size 
expressed as a percentage of the area at risk. Numbers in histograms indicate
sample size.  ** p<0.01 versus Control; *** p<0.001 versus control; † p<0.01 versus 
GYY4137 (one way ANOVA with Newman Keuls post hoc test). 
Figure 4. Western blot analysis of left ventricular myocardium harvested from the 
area at risk 5 minutes after reperfusion. Histograms show densitometric ratios of 
phosphorylated to total protein. GAPDH was used as loading control for all 
determinations. A. p-Akt, total Akt and GAPDH. B. p-eNOS, total eNOS and 
GAPDH. C. p-GSK-3β, total GSK-3β and GAPDH. D. p-ERK1/2, total ERK1/2 and 
GAPDH. * p < 0.05, ** p,0.01, *** p<0.001 versus control. In all groups, n=4.
Figure 5 (Graphical abstract)
GYY4137, a donor of H2S, induces marked limitation of myocardial infarct size when 
given shortly before reperfusion. Based on the present experimental data, we 
present a mechanistic scheme by which GYY4137 mediates its cardioprotection 
against reperfusion injury. GYY4137 releases H2S which triggers a key component 
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of the reperfusion injury salvage kinase cascade, namely PI3K/Akt activation at 
reperfusion. Downstream of activated Akt, phosphorylation of eNOS and GSK-3are 
induced by GYY4137 treatment. Although not yet determined, it seems plausible that 
GYY4137 eventually inhibits the opening of mPTP at early reperfusion as a result of 
the increase in NO level and inhibition GSK-3β activity, resulting in reduced 
cardiomyocyte susceptibility to lethal reperfusion injury.
Table 1.
Baseline and cardiodynamics for series 1 and 2 at the end of stabilisation period, 
after 20 minutes of ischaemia and at the end of reperfusion.
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(Figure 1)
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(Figure 2)
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(Figure 3)
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(Figure 4)
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(Figure 5)
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Table 1.
RPP=rate pressure product, MAP=mean arterial pressure. Data are reported as Mean ±
SEM. There was no significant difference among the experimental groups (One way ANOVA 
+ Newman Keuls post-hoc), p > 0.05.
Experimental 
Protocol
n BW 
(g)
Baseline 20 min Ischaemia 120 min Reperfusion
RPP 
(mmHg min-
1*103)
MAP 
(mmH
g)
RPP 
(mmHg min-
1*103)
MAP 
(mmH
g)
RPP 
(mmHg min-
1*103)
MAP 
(mmH
g)
Series 1
Control 10 355 ± 
6
37.5 ± 2.0 88 ± 4
27.9 ± 1.8 68 ± 4 24.0 ± 1.4 53 ± 3
GYY4137 26.6 
µmol kg-1
8 360 ± 
9
40.3 ± 3.0 90 ± 6
29.1 ± 2.1 71 ± 5 26.3 ± 2.0 59 ± 4
GYY4137 133 
µmol kg-1
8 346 ± 
7
41.4 ± 1.8 94 ± 6
29.5 ± 2.2 70 ± 6 24.3 ± 1.5 53 ± 4
GYY4137 266 
µmol kg-1
8 368 ± 
6
39.1 ± 1.7 83 ± 4
28.6 ± 2.0 65 ± 5 20.9 ± 1.6 45 ± 3
D-GYY4137 6 368 ± 
6
38.4 ± 2.3 85 ± 5 26.3 ± 2.1 69 ± 4 22.7 ± 1.3 48 ± 4
Series 2
Control 7 384 ± 
7
36.3 ± 2.2 85 ± 5
24.8 ± 2.2 61 ± 6 21.2 ± 2.0 48 ± 4
GYY4137 7 379 ± 
8
41.3 ± 3.0 96 ± 6
26.8 ± 1.6 66 ± 6 21.6 ± 1.1 47 ± 2
GYY4137 + L-
NAME
7 387 ± 
7
39.3 ± 2.5 88 ± 5
29.5 ± 2.4 69 ± 5 19.4 ± 2.4 50 ± 6
L-NAME 6 381 ± 
9
39.3 ± 1.6 97 ± 3
30.4 ± 2.1 76 ± 7 22.4 ± 5.1 57 ± 9
GYY4137 + 
LY294002
6 362 ± 
8
39.3 ± 1.8 88 ± 4
30.2 ± 1.8 71 ± 5 24.2 ± 0.6 53 ± 1
LY294002 6 367 ± 
11
44.5 ± 2.8 98 ± 4
29.6 ± 1.2 72 ± 4 25.0 ± 0.7 54 ± 2
